ANIK: מכפיל P/E עתידי Anika Therapeutics

Anika Therapeutics is developing its tissue and joint regeneration segment, ensuring stable supplies to clinics. The company creates safe biomaterials while maintaining strict control over production waste disposal. This price chart shows that the current P/E ratio for Anika Therapeutics (ANIK) shares stands at 12.80. The visualization below allows for a real-time assessment of the market value of this specialized medical device manufacturer.
Anika Therapeutics, Inc. (ANIK) - פילוחי מדדים ודוחות פיננסיים

Patent protection for Anika Therapeutics (ANIK) products enables the company to maintain premium pricing within regenerative medicine. The trend of the company's forward P/E NTM illustrates market expectations regarding this profitability. This ratio correlates the current share price with the projected net income for the following year. Low values signal that the asset is undervalued, while inflated levels increase the risk of a correction. This indicator confirms the resilience of the business model during the execution of financial plans.